Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome

Leukemia Research

Volumn 23, Issue 1, 1999, Pages 77-83

  Miller, Alan M ^a   Noyes, Ward E ^b   Taetle, Raymond ^c   List, Alan F ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Colony forming units; Erythropoietin; Hematopoietic growth factors; Interleukin 3; Myelodysplastic syndrome; Therapy

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 3;

ADULT; AGED; ARTICLE; BURST FORMING UNIT E; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED STUDY; DYSPNEA; EDEMA; ERYTHROPOIESIS; FATIGUE; FEMALE; FEVER; HUMAN; MALE; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETICULOCYTE; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

AGED; BLOOD CELL COUNT; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATIENT DROPOUTS;

EID: 0032890364     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00127-1     Document Type: Article

References (29)

1. List A, Garewal H, Sandberg A. The myelodysplastic syndromes: biology and implications for management. J Clin Oncol 1990;8:1424.
2. Cheson B. The myelodysplastic syndromes: current approaches to therapy. Ann Intern Med 1990;112:932.
3. Zwierzina H, Mufti G, Schmalzi F. Therapy of myelodysplastic syndromes: advances and perspectives. Leukemia 1991;5:166.
4. Appelbaum FR, et al. Treatment of preleukemic syndromes with marrow transplantation. Blood 1987;69:92.
5. Appelbaum FR, et al. Bone marrow transplantation for patients with myelodysplasis. Pretreatment variables and outcome. Ann Intern Med 1990;112:590.
6. Longmore G, et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 1990;8:1707.
7. O'Donnell MR, et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987;5:1822.
8. Bowen D, Culligan D, Jacobs A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991;77:419.
9. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991;78:1658.
10. Stebler C, et al. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Hematol 1990;18:1204.
11. Vadhan-Raj S, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. New Engl J Med 1987;317:1545.
12. Antin JH, et al. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988;72:70.
13. Negrin RS, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann Intern Med 1989;110:976.
14. Kobayashi Y, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. Am J Med 1989;86:178.
15. Stein RS. Clinical use of growth factors in the myelodysplastic syndromes. Am J Med Sci 1994;307:360.
16. Ganser A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990;76:455.
17. Jacobs A, Janoswka-Wieczorek A, Caro J, et al. Circulating erythropoietin in patients with myelodysplasia. Br J Haematol 1991;77:419.
18. Ruutu T, Partanen S, Lintula R, et al. Erythroid and granulocyte-macrophage colony formation in myelodysplasia syndromes. Scand J Haematol 1984;32:395.
19. Merchav S, Wagemaker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant hematopoietic growth factors. Leukemia 1991;5:340.
20. Lopez AF, Dyson PG, Bik L, et al. Recombinant human interleukin-3 stimulation of hematopoiesis in humans: loss of responsiveness with differentiation in the neutrophilic myeloid series. Blood 1988;72:1797.
21. Caracciolo D, Clark S, Rovera G. Differential activity of recombinant colony-stimulating factors in supporting proliferation of human peripheral blood and bone marrow myeloid progenitors in culture. Br J Haematol 1989;72:306.
22. Migliaccio G, Migliaccio AG, Visser JWM. Synergism between erythropoietin and interleukin-3 in the induction of hematopoietic stem cell proliferation and erythroid burst colony formation. Blood 1988;72:944.
23. Umemura T, et al. Effects of interleukin-3 and erythropoiesis and F-cell formation in primates. Blood 1989;74:1571.
24. Negrin RS, et al. Maintenance treatment of anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076.
25. Hellström-Lindberg E, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the aneamia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99:344.
26. Imai Y, et al. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokine (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone. Br J Haematol 1996;93:146.
27. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borof R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268.
28. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showell J, Loew J. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265.
29. Ganser A, Ottman OG, Seipelt G, Lindemann A, Hess U, Geisser G, Maurer A, Frisch J, Schulz G, Mertelsman R, Hoelzer D. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993;7: 696.